Univariate analysis of overall survival in all pancreatic ductal adenocarcinoma patients revealed that cases significantly associated with shorter survival included those with larger tumor sizes (≥35 mm, P = 0.001), lymph node metastases (P = 0.005), distant metastasis (P = 0.004), advanced stage (stage IIB or III, P = 0.006), advanced tumor histological grade (G3, P < 0.001), or positive intraoperative PLC (P = 0.002) (Table 3). Here, HSPG2 is linked to pancreatic ductal adenocarcinoma.